Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo

被引:22
|
作者
Olsen, Elise A. [1 ]
Whiting, David A. [2 ]
Savin, Ronald [3 ]
Rodgers, Anthony [4 ]
Johnson-Levonas, Amy O. [4 ]
Round, Elizabeth [4 ]
Rotonda, Jennifer [4 ]
Kaufman, Keith D. [4 ]
机构
[1] Duke Univ, Med Ctr, DUMC, Durham, NC 27710 USA
[2] Hair & Skin Res & Treatment Ctr, Dallas, TX USA
[3] Savin Dermatol Ctr, New Haven, CT USA
[4] Merck, Whitehouse Stn, NJ USA
关键词
androgenetic alopecia; dihydrotestosterone; finasteride; male pattern hair loss; 5 alpha-reductase inhibitor; ANDROGENETIC ALOPECIA; BALDNESS; EFFICACY; GROWTH;
D O I
10.1016/j.jaad.2011.10.027
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Finasteride (1 mg) has been shown to increase vertex hair growth in men aged 18 to 60 years with male pattern hair loss and to increase frontal scalp hair growth in subjects aged 18 to 41 years. Objective: A secondary efficacy analysis was conducted to determine effects of finasteride (1 mg) on scalp hair growth in the 4 distinct scalp regions affected by male pattern hair loss. Methods: Multicenter, double-blind studies randomized patients with vertex hair loss (men aged 18-41 and 41-60 years) to finasteride (1 mg/d) or placebo. Efficacy was evaluated by review of standardized clinical photographs (global photographic assessment) of the vertex, anterior/mid scalp regions, and frontal and temporal hairlines over 24 months relative to baseline. Results: At 24 months, treatment with finasteride resulted in statistically significant (P <= .05) hair growth versus placebo in all scalp regions. There was also a significant decrease in hair loss in the younger men treated with finasteride in all areas, but only in the vertex and anterior/mid scalp regions in the older men. A slightly higher incidence of drug-related sexual adverse experiences was reported in the finasteride group than in the placebo group, irrespective of age. Limitations: These studies enrolled men with vertex pattern hair loss; therefore, the findings may not be extrapolated to men with predominantly anterior/mid scalp, frontal, or temporal hair loss. Conclusion: Based on global photographic assessment, finasteride (1 mg) is able to increase hair growth in all areas of the scalp affected by male pattern hair loss. (J Am Acad Dermatol 2012;67:379-86.)
引用
收藏
页码:379 / 386
页数:8
相关论文
共 15 条
  • [1] Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss
    Whiting, DA
    Olsen, EA
    Savin, R
    Halper, L
    Rodgers, A
    Wang, LX
    Hustad, C
    Palmisano, J
    EUROPEAN JOURNAL OF DERMATOLOGY, 2003, 13 (02) : 150 - 160
  • [2] Finasteride, 1 mg (Propecia), is the optimal dose for the treatment of men with male pattern hair loss
    Kaufman, KD
    ARCHIVES OF DERMATOLOGY, 1999, 135 (08) : 989 - 990
  • [3] Finasteride in the treatment of men with frontal male pattern hair loss
    Leyden, J
    Dunlap, F
    Miller, B
    Winters, P
    Lebwohl, M
    Hecker, D
    Kraus, S
    Baldwin, H
    Shalita, A
    Draelos, Z
    Markou, M
    Thiboutot, D
    Rapaport, M
    Kang, SW
    Kelly, T
    Pariser, D
    Webster, G
    Hordinsky, M
    Rietschel, R
    Katz, HI
    Terranella, L
    Best, S
    Round, E
    Waldstreicher, J
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 40 (06) : 930 - 937
  • [4] Finasteride in the treatment of Japanese men with male pattern hair loss
    Kawashima, M
    Hayashi, N
    Igarashi, A
    Kitahara, H
    Maeguchi, M
    Mizuno, A
    Murata, Y
    Nogita, T
    Toda, K
    Tsuboi, R
    Ueki, R
    Yamada, M
    Yamazaki, M
    Matsuda, T
    Natsumeda, Y
    Takahashi, K
    Harada, S
    EUROPEAN JOURNAL OF DERMATOLOGY, 2004, 14 (04) : 247 - 254
  • [5] Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss)
    Shapiro, J
    Kaufman, KD
    JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 2003, 8 (01) : 20 - 23
  • [6] Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss)
    Kaufman, Keith D.
    Rotonda, Jennifer
    Shah, Arvind K.
    Meehan, Alan G.
    EUROPEAN JOURNAL OF DERMATOLOGY, 2008, 18 (04) : 400 - 406
  • [7] Prevalence of male pattern hair loss in 18-49 year old men
    Rhodes, T
    Girman, CJ
    Savin, RC
    Kaufman, KD
    Guo, SM
    Lilly, FRW
    Siervogel, RM
    Chumlea, WC
    DERMATOLOGIC SURGERY, 1998, 24 (12) : 1330 - 1332
  • [8] Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss
    Roberts, JL
    Fiedler, V
    Imperato-McGinley, J
    Whiting, D
    Olsen, E
    Shupack, J
    Stough, D
    DeVillez, R
    Rietschel, R
    Savin, R
    Bergfeld, W
    Swinehart, J
    Funicella, T
    Hordinsky, M
    Lowe, N
    Katz, I
    Lucky, A
    Drake, L
    Price, VH
    Weiss, D
    Whitmore, E
    Millikan, L
    Muller, S
    Gencheff, C
    Carrington, P
    Binkowitz, B
    Kotey, P
    He, W
    Bruno, K
    Jacobsen, C
    Terranella, L
    Gormley, GJ
    Kaufman, KD
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (04) : 555 - 563
  • [9] Occurrence of male pattern hair loss in 18 to 49 year old men in the United-States
    Rhodes, T
    Girman, CJ
    Kaufman, KD
    Flavis, RW
    Guo, SM
    Sieryogel, RM
    Chumlea, WC
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (02) : 200 - 200
  • [10] The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss:: Results of a randomized placebo-controlled study of dutasteride versus finasteride
    Olsen, Elise A.
    Hordinsky, Maria
    Whiting, David
    Stough, Dow
    Hobbs, Stuart
    Ellis, Melissa L.
    Wilson, Timothy
    Rittmaster, Roger S.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (06) : 1014 - 1023